Overview: Tissue Transglutaminase IgG TestIntroduction: The Tissue Transglutaminase IgG Test detects tTG IgG to diagnose celiac disease, causing abdominal pain. Following 2023 AGA guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected celiac disease, especially in IgA-deficient patients.
Other Names: tTG IgG Assay, Anti-tTG IgG Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: tTG IgG testing began in the 2000s with celiac research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects tTG IgG to diagnose celiac disease, guides treatment, and evaluates patients with abdominal pain.
Test Parameters: 1. tTG IgG Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of abdominal pain or gastrointestinal symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document abdominal pain, diarrhea, or history of celiac disease. Include current medications, especially gluten exposure.
Consent: Written consent required, detailing the tests purpose, celiac disease implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect tTG IgG antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for celiac disease diagnosis in IgA-deficient patients.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Gluten-free diet may cause false negatives.
Clinical Significance: Positive tTG IgG confirms celiac disease, guiding gluten-free diet or further testing. Negative results may require endomysial antibodies or biopsy.
Specialist Consultation: Consult a gastroenterologist for result interpretation and treatment planning.
Additional Supporting Tests: tTG IgA, endomysial antibodies, or small bowel biopsy to confirm celiac disease diagnosis.
Test Limitations: Less sensitive in non-IgA-deficient patients; clinical correlation is needed. Sample quality affects sensitivity.
References: AGA Celiac Disease Guidelines, 2023; Gastroenterology, Husby S, 2022.
